JP2010522774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522774A5 JP2010522774A5 JP2010501409A JP2010501409A JP2010522774A5 JP 2010522774 A5 JP2010522774 A5 JP 2010522774A5 JP 2010501409 A JP2010501409 A JP 2010501409A JP 2010501409 A JP2010501409 A JP 2010501409A JP 2010522774 A5 JP2010522774 A5 JP 2010522774A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- combination according
- angiogenic
- calcineurin inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000001772 anti-angiogenic effect Effects 0.000 claims 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
- 108010036949 Cyclosporine Proteins 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 3
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 3
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229960002800 prednisolone acetate Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000007998 vessel formation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360012 | 2007-03-30 | ||
| PCT/EP2008/002426 WO2008119500A1 (en) | 2007-03-30 | 2008-03-27 | Methods for treating neovascular ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522774A JP2010522774A (ja) | 2010-07-08 |
| JP2010522774A5 true JP2010522774A5 (cg-RX-API-DMAC7.html) | 2011-05-19 |
Family
ID=39564402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501409A Pending JP2010522774A (ja) | 2007-03-30 | 2008-03-27 | 血管新生眼疾患を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100233194A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2139492A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010522774A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101678034A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008234141A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2681361A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008119500A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722015B2 (en) * | 2010-04-01 | 2014-05-13 | The Schepens Eye Research Institute, Inc. | Compositions and methods for treatment of angiogenesis-associated ocular disorders |
| WO2011161295A2 (es) * | 2010-06-23 | 2011-12-29 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular |
| MA41818A (fr) * | 2015-03-27 | 2018-01-30 | Leo Pharma As | Timbre à micro-aiguilles pour administration d'un principe actif à la peau |
| US11229662B2 (en) | 2016-11-15 | 2022-01-25 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| JP7416700B2 (ja) | 2017-11-14 | 2024-01-17 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法 |
| EP3866788B1 (en) * | 2018-10-19 | 2023-12-13 | MediciNova, Inc. | Treatment of macular injury associated with multiple sclerosis with ibudilast |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| WO2006039558A2 (en) | 2004-10-09 | 2006-04-13 | Formurex, Inc. | Ocular agent delivery systems |
| US20060148686A1 (en) * | 2004-12-30 | 2006-07-06 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| CA2615990A1 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
| US20070087962A1 (en) * | 2005-10-17 | 2007-04-19 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| DE102006051512A1 (de) * | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
-
2008
- 2008-03-27 JP JP2010501409A patent/JP2010522774A/ja active Pending
- 2008-03-27 EP EP08716704A patent/EP2139492A1/en not_active Withdrawn
- 2008-03-27 US US12/593,758 patent/US20100233194A1/en not_active Abandoned
- 2008-03-27 CA CA002681361A patent/CA2681361A1/en not_active Abandoned
- 2008-03-27 AU AU2008234141A patent/AU2008234141A1/en not_active Abandoned
- 2008-03-27 WO PCT/EP2008/002426 patent/WO2008119500A1/en not_active Ceased
- 2008-03-27 CN CN200880010884A patent/CN101678034A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522774A5 (cg-RX-API-DMAC7.html) | ||
| Mentz et al. | The past, present and future of renin–angiotensin aldosterone system inhibition | |
| Ponticelli et al. | Hypertension in kidney transplant recipients | |
| Seeland et al. | Sex and gender differences in cardiovascular drug therapy | |
| Graziani et al. | Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis | |
| JP2017503820A5 (cg-RX-API-DMAC7.html) | ||
| JP2018039833A5 (cg-RX-API-DMAC7.html) | ||
| Goldsmith et al. | Intestinal epithelial cell–derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K Signaling | |
| JP2021523103A (ja) | Ｉｌ−３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| JP2015057436A5 (cg-RX-API-DMAC7.html) | ||
| JP2009513660A5 (cg-RX-API-DMAC7.html) | ||
| EP2598158A4 (en) | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex | |
| JP2016538270A5 (cg-RX-API-DMAC7.html) | ||
| JP2010514834A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504436A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513809A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510081A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533220A5 (cg-RX-API-DMAC7.html) | ||
| MX393629B (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| Dey et al. | Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension | |
| Martin-Ventura et al. | Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis: New strategies to prevent cardiovascular risk in chronic kidney disease | |
| Chouinard et al. | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia | |
| Chatzikyrkou et al. | Update on treatment of hypertension after renal transplantation | |
| Mahmoudabady et al. | The effect of angiotensin-converting enzyme inhibition on inflammatory and angiogenic factors in hypercholesterolemia | |
| Kühnast et al. | Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE* 3Leiden. CETP transgenic mice with or without treatment with atorvastatin |